

Irene Cano-Pumarega

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7920049/publications.pdf>

Version: 2024-02-01

36
papers

992
citations

430442

18
h-index

433756

31
g-index

37
all docs

37
docs citations

37
times ranked

1116
citing authors

#	ARTICLE	IF	CITATIONS
1	Moderate obstructive sleep apnea and cardiovascular outcomes in older adults: a propensity score-matched multicenter study (CPAGE-MODE study). <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 553-561.	1.4	2
2	[Translated article] International consensus document on obstructive sleep apnea. <i>Archivos De Bronconeumologia</i> , 2022, 58, T52-T68.	0.4	10
3	Untreated obstructive sleep apnea and cardiovascular outcomes in patients with acute symptomatic pulmonary embolism. <i>Thrombosis Research</i> , 2022, 214, 87-92.	0.8	4
4	Special considerations for treatment of sleep-related movement disorders. , 2021, , .		0
5	Sleep-Related Rhythmic Movement Disorder. <i>Sleep Medicine Clinics</i> , 2021, 16, 315-321.	1.2	9
6	Restless Legs Syndrome - Clinical Features. <i>Sleep Medicine Clinics</i> , 2021, 16, 233-247.	1.2	4
7	Correlation between systemic iron parameters and substantia nigra iron stores in restless legs syndrome. <i>Sleep Medicine</i> , 2021, 85, 191-195.	0.8	6
8	Upcoming Scenarios for the Comprehensive Management of Obstructive Sleep Apnea: An Overview of the Spanish Sleep Network. <i>Archivos De Bronconeumologia</i> , 2020, 56, 35-41.	0.4	9
9	Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome. <i>Sleep Medicine</i> , 2020, 66, 123-129.	0.8	21
10	Obesity attenuates the effect of sleep apnea on active TGF- β 1 levels and tumor aggressiveness in patients with melanoma. <i>Scientific Reports</i> , 2020, 10, 15528.	1.6	8
11	Proangiogenic factor midkine is increased in melanoma patients with sleep apnea and induces tumor cell proliferation. <i>FASEB Journal</i> , 2020, 34, 16179-16190.	0.2	11
12	Iron Replacement Therapy in Restless Legs Syndrome. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1.	0.7	6
13	Low risk of iron overload or anaphylaxis during treatment of restless legs syndrome with intravenous iron: a consecutive case series in a regular clinical setting. <i>Sleep Medicine</i> , 2020, 74, 48-55.	0.8	5
14	Emerging Concepts of the Pathophysiology and Adverse Outcomes of Restless Legs Syndrome. <i>Chest</i> , 2020, 158, 1218-1229.	0.4	17
15	Obstructive Sleep Apnea: Emerging Treatments Targeting the Genioglossus Muscle. <i>Journal of Clinical Medicine</i> , 2019, 8, 1754.	1.0	34
16	Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome. <i>Advances in Pharmacology</i> , 2019, 84, 187-205.	1.2	17
17	Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. <i>Sleep Medicine</i> , 2019, 55, 74-80.	0.8	25
18	Continuous Positive Airway Pressure Treatment Does not Reduce Uric Acid Levels in OSA Women. <i>Archivos De Bronconeumologia</i> , 2019, 55, 201-207.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients. <i>European Respiratory Journal</i> , 2019, 53, 1801298.	3.1	27
20	Treating restless legs syndrome in the context of sleep disordered breathing comorbidity. <i>European Respiratory Review</i> , 2019, 28, 190061.	3.0	15
21	Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. <i>Sleep Medicine</i> , 2018, 45, 94-97.	0.8	44
22	Management of treatment failure in restless legs syndrome (Willis-Ekbom disease). <i>Sleep Medicine Reviews</i> , 2018, 41, 50-60.	3.8	25
23	Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea. <i>European Respiratory Journal</i> , 2018, 51, 1701885.	3.1	27
24	Sleep-Disordered Breathing Is Independently Associated With Increased Aggressiveness of Cutaneous Melanoma. <i>Chest</i> , 2018, 154, 1348-1358.	0.4	58
25	Intermittent Hypoxia Is Associated With High Hypoxia Inducible Factor-1 α but Not High Vascular Endothelial Growth Factor Cell Expression in Tumors of Cutaneous Melanoma Patients. <i>Frontiers in Neurology</i> , 2018, 9, 272.	1.1	16
26	New concepts in the management of restless legs syndrome. <i>BMJ: British Medical Journal</i> , 2017, 356, j104.	2.4	61
27	Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial. <i>BMC Pulmonary Medicine</i> , 2017, 17, 8.	0.8	30
28	Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel. <i>Sleep Medicine</i> , 2017, 34, 105-108.	0.8	44
29	Sleep Apnea and Hypertension. <i>Chest</i> , 2017, 152, 742-750.	0.4	51
30	A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1 α and VEGF expressions. <i>Melanoma Research</i> , 2017, 27, 558-564.	0.6	23
31	Effect of continuous positive airway pressure on blood pressure and metabolic profile in women with sleep apnoea. <i>European Respiratory Journal</i> , 2017, 50, 1700257.	3.1	30
32	Impact of obstructive sleep apnea on cardiovascular outcomes in patients with acute symptomatic pulmonary embolism: Rationale and methodology for the POPE study. <i>Clinical Cardiology</i> , 2017, 40, 1182-1188.	0.7	13
33	Sex differences in the association between obstructive sleep apnea and hypertension—what’s next?. <i>Journal of Thoracic Disease</i> , 2017, 9, E1156-E1157.	0.6	1
34	Continuous Positive Airway Pressure Improves Quality of Life in Women with Obstructive Sleep Apnea. A Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1286-1294.	2.5	71
35	Obstructive Sleep Apnea and Systemic Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1299-1304.	2.5	151
36	Recurrent tuberculosis from 1992 to 2004 in a metropolitan area. <i>European Respiratory Journal</i> , 2007, 30, 333-337.	3.1	32